MARKET

ONCE

ONCE

Spark
NASDAQ

Real-time Quotes | Nasdaq Last Sale

110.81
0.00
0.00%
Closed 16:50 11/15 EST
OPEN
110.60
PREV CLOSE
110.81
HIGH
111.03
LOW
110.30
VOLUME
287.42K
TURNOVER
--
52 WEEK HIGH
114.20
52 WEEK LOW
34.53
MARKET CAP
4.27B
P/E (TTM)
-16.9284
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONCE News

  • Best-Performing Small-Cap Stocks YTD: November 2019
  • Seeking Alpha - Article.4d ago
  • Merger Arbitrage Analysis And Spread Performance - November 03, 2019
  • Seeking Alpha - Article.6d ago
  • 7 Philadelphia-area companies make Deloitte fastest-growing list
  • American City Business Journals.6d ago
  • Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
  • Seeking Alpha - Article.11/04 14:03

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About ONCE

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
More

Webull offers Spark Therapeutics Inc (ONCE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.